EPIGRAL Share Price

Newpaper Publication - Un-Audited Financial Results for the First Quarter ended 30.06.2026

• BSE India
• 2 hours 8 minutes ago

Audio Recording of Conference Call discussing Q1 FY27 Results held on Monday, 27th July, 2026 at 5.00 p.m.

• BSE India
• 1 day 19 hours ago

<h3><span style="font-size:16px;"><strong>Specialty Chemicals company Epigral announced Q1FY27 results</strong></span></h3><p _ngcontent-ng-c119449379=""><strong _ngcontent-ng-c119449379="">Standalone Financial Highlights:</strong></p><ul><li _ngcontent-ng-c119449379="">The company reported a Revenue from operations of Rs 705.36 crore in Q1FY27, representing a YoY increase of 16.29% from Rs 606.54 crore in Q1FY26, and a QoQ decrease of 4.18% from Rs 736.16 crore in Q4FY26.</li><li _ngcontent-ng-c119449379="">Total income for Q1FY27 stood at Rs 709.46 crore, compared to Rs 614.79 crore in Q1FY26 (up 15.40% YoY) and Rs 735.59 crore in Q4FY26 (down 3.55% QoQ).</li><li _ngcontent-ng-c119449379="">Profit before tax (PBT) for Q1FY27 was Rs 133.18 crore, marking a YoY growth of 24.78% from Rs 106.73 crore in Q1FY26 and a QoQ growth of 20.50% from Rs 110.52 crore in Q4FY26.</li><li _ngcontent-ng-c119449379="">Profit after tax (PAT) for Q1FY27 was Rs 99.18 crore, a decrease of 38.17% YoY from Rs 160.41 crore in Q1FY26 (which included a one-time deferred tax credit), but an increase of 21.05% QoQ from Rs 81.93 crore in Q4FY26.</li><li _ngcontent-ng-c119449379="">The Total Comprehensive Income for Q1FY27 was Rs 99.19 crore, compared to Rs 160.29 crore in Q1FY26 and Rs 82.52 crore in Q4FY26.</li><li _ngcontent-ng-c119449379="">Earnings per share (Basic and Diluted) for Q1FY27 was Rs 22.99, compared to Rs 37.18 in Q1FY26 and Rs 18.99 in Q4FY26.</li></ul><p _ngcontent-ng-c119449379=""><strong _ngcontent-ng-c119449379="">Consolidated Financial Highlights: </strong></p><ul><li _ngcontent-ng-c119449379="">Consolidated Revenue from operations in Q1FY27 was Rs 705.36 crore, showing a YoY growth of 16.29% from Rs 606.54 crore in Q1FY26 and a QoQ decline of 4.18% from Rs 736.16 crore in Q4FY26.</li><li _ngcontent-ng-c119449379="">Total income for the quarter ended Q1FY27 was Rs 709.46 crore, up 15.40% YoY from Rs 614.79 crore in Q1FY26 and down 3.55% QoQ from Rs 735.59 crore in Q4FY26.</li><li _ngcontent-ng-c119449379="">Profit before tax (PBT) reached Rs 133.74 crore in Q1FY27, an increase of 24.98% YoY from Rs 107.01 crore in Q1FY26 and a 22.09% QoQ increase from Rs 109.54 crore in Q4FY26.</li><li _ngcontent-ng-c119449379="">Profit after tax (PAT) for Q1FY27 stood at Rs 99.74 crore, a YoY decrease of 37.93% from Rs 160.69 crore in Q1FY26 and a QoQ increase of 23.21% from Rs 80.95 crore in Q4FY26.</li><li _ngcontent-ng-c119449379="">Total Comprehensive Income for Q1FY27 was Rs 99.75 crore, as against Rs 160.57 crore in Q1FY26 and Rs 81.54 crore in Q4FY26.</li><li _ngcontent-ng-c119449379="">The consolidated Revenue from operations for the full year FY26 was Rs 2,527.18 crore with a PAT of Rs 331.97 crore.</li><li _ngcontent-ng-c119449379="">Consolidated Earnings per share (Basic and Diluted) for Q1FY27 was Rs 23.12, compared to Rs 37.25 in Q1FY26 and Rs 18.76 in Q4FY26.</li></ul><p _ngcontent-ng-c119449379=""><strong _ngcontent-ng-c119449379="">Business Highlights:</strong></p><ul><li _ngcontent-ng-c119449379=""><strong _ngcontent-ng-c119449379="">Subsidiary Incorporation:</strong> Subsequent to the quarter ended June 30, 2026, the company incorporated a wholly owned subsidiary named "Epigral Advanced Material Limited" on July 07, 2026, with the objective of manufacturing chemicals.</li><li _ngcontent-ng-c119449379=""><strong _ngcontent-ng-c119449379="">Power Project Investment:</strong> During FY26, the company entered into agreements to invest in 'Prozeal Green Power Private Limited' and 'Pro-Zeal Green Power Ten Private Limited' for a 19.80 MW Wind Solar Hybrid Power plant in Gujarat. The company has agreed to invest Rs 0.13 crore for 26% equity share capital and Rs 21.25 crore in Optionally Convertible Debentures.</li><li _ngcontent-ng-c119449379=""><strong _ngcontent-ng-c119449379="">Energy Supply Agreement:</strong> The company entered into an "Energy Supply Agreement" to purchase a minimum of 51% of the power generated by the hybrid power plant for a period of 25 years. The plant is expected to commence operations in the near future.</li><li _ngcontent-ng-c119449379=""><strong _ngcontent-ng-c119449379="">Taxation:</strong> Effective from FY26, the company exercised the option under Section 115BAA of the Income-tax Act, 1961, to pay tax at a reduced rate. This resulted in a one-time deferred tax credit of Rs 80.87 crore recognized in Q1FY26 and FY26.</li></ul><p><strong>Maulik Patel, Chairman & Managing Director, Epigral, said:</strong> “Epigral delivered steady growth in Q1FY27 despite severe macroeconomic volatility driven by geopolitical tensions in West Asia. The quarter was marked by fluctuations in raw material and finished goods prices, alongside elevated freight costs and shipment delays. Leveraging its diversified product mix, Epigral successfully navigated these headwinds to achieve 15% revenue growth and an EBITDA margin of 25%.</p><p>While geopolitical challenges persist, operating conditions have stabilized. Backed by India’s strong economic growth trajectory, management maintains a positive outlook. To drive future diversified growth, the Board approved strategic investments in a new Epoxy Resin & Formulations plant and a Multi-Purpose Plant (MPP). Both expansions will enhance efficiency within Epigral’s integrated manufacturing complex by utilizing internal raw materials. Specifically, the Epoxy Resin plant will consume ECH and Caustic Soda, while the MPP will be downstream of Epichlorohydrin and Chlorotoluenes Value Chain.</p><p>The Epoxy Resin plant will cater to domestic and global demand across the renewable energy, infrastructure, electronics, automotive, and industrial sectors. Concurrently, the MPP will meet rising domestic demand for pharmaceutical and agrochemical intermediates and water treatment chemicals.</p><p>These investments reflect Epigral's ongoing commitment to building an integrated manufacturing platform and diversifying its portfolio to deliver long-term stakeholder value.”</p><p><a class="lb" href="/hindi/get-document/post/pdf/5748773/" target="_blank">Result PDF</a></p>

• Trendlyne
• 2 days 3 hours ago